- Archer Exploration is now Archer Materials
- The rename reflects its focus as a materials technology company
- Archer is progressing its lead assets as it moves to commercialising its technology
We have reached a key development milestone to commercially exploit the IP underpinning the graphene-based biosensor technology.
Archer Materials chief executive officer Dr Mohammad Choucair
What does Archer Materials do?
The ASX-listed company, previously known as Archer Exploration Limited, recently completed a rename as a materials technology company after making a number of steps towards commercialising its lead assets.
Among these steps is progress in developing its graphene-based biosensor technology along with advancing qubit and biosensor technologies.
The Sydney-headquartered advanced materials business of the company has built a first-phase prototype device (prototype) to test the patterning, printing and performance of graphene inks.
These inks have been produced from an inventory controlled by Archer’s wholly-owned subsidiary Carbon Allotropes and act as biosensor components.
Archer recently reported that the inks were successfully printed and tested in a biosensing prototype device.
The collaborative company believes its printing process could be duplicated and automated, to facilitate “market-competitive” low-cost prototype production.
Intellectual property ownership for the inks and prototype technologies remain with Archer group which holds a provisional patent for the assets.
The company plans to continue commercialising its biosensor technologies and take its prototypes from proof of concept to patent application stage.
Archer chief executive officer Dr Mohammad Choucair reported this morning: “We have reached a key development milestone to commercially exploit the IP underpinning the graphene-based biosensor technology.
“This achievement provides support for a full patent application that would give Archer exclusive rights to commercially benefit from the IP.
“The materials and processes used to build the prototypes are not prohibitively expensive, which is an advantage in the printable biosensor market.”
Who leads Archer Materials?
Dr Choucair leads Archer with executive chairman Greg English.
Choucair is a Nanotechnology specialist and executive who has more than 12 years’ experience in commercialisation and deep tech development and has served on the World Economic Forum’s Global Council for Advanced Materials.
His achievements include inventing the first method known to chemically produce graphene in bulk quantities, to overcome a production limitation by allowing non-graphitic carbon feedstocks to be used in the preparation of graphene, effectively making the material globally accessible.
Lawyer, engineer and chairman English is a partner at Piper Alderman. The experienced director also co-founded Archer and has overseen the company’s transition from a South Australian focused minerals exploration company to a diverse materials technology company.
What are Archer Materials’ next steps?
Archer hopes to take its graphene technologies to market and position itself as a competitive player in a commercial space.
The company said today its next steps included “manufacturing a commercially viable graphene-based biosensor technology and the registration of a full patent application protecting the underlying materials technology IP.
“This involves optimising ink formulations and their processing methods linked to the provisional patent claims and identifying transduction methods, bioreceptors, analytes, coupling and assay reagents for the proper function of the biosensor technology.
“Archer intends to commercialise the biosensing technology by seeking to establish commercial partnerships, including licencing agreements, with highly resourced organisations including biotechnology companies, that could allow for product scale, IP transfer, and distribution channels.”
- Commercialisation milestones, including intellectual property and prototyping wins and demonstration milestones
- Advanced materials technology development and cost price reductions
- Growth in biotechnology and point-of-care health management
- Financing milestones and key transactions
- Merger & acquisitions activity in Australia and abroad